Werner Gladdines

📢 Patent Update 🛡️ The European Patent Office, @EPOorg, has granted a key European patent covering label-relevant dosing regimens for #Immunic’s lead candidate, our #Nurr1 activator and #DHODH inhibitor, across all indications, including #MultipleSclerosis (#MS). 🇪🇺 💊 The patent broadly protects #vidofludimus and its salt, solvate and free acid forms used according to the label-mandated dosing scheme. It is expected to provide protection in Europe into 2038 and may be eligible for a Supplementary Protection Certificate (SPC), potentially extending market exclusivity into 2043.🧠 🧩 The #patent was previously granted by the U.S. Patent and Trademark Office, @uspto, in 2023 and supports Immunic’s multi-layered #IntellectualProperty strategy for the drug with protection expected at least into 2041 in the United States and 2039 in Europe. 👉 Learn more here: bit.ly/46Tyqg9 #DrugDevelopment $IMUX #IMU838

We are #hiring a working student in #communications! Are you creative, communicative, and ready to dive into the world of #biotech? Join our #PR and #IR team in Gräfelfing, just outside of Munich! ✨ Curious about public and investor relations at #Immunic, learn more here: 👉 imux.com/careers $IMUX #nowhiring #jobopportunity #applynow

📢 #Immunic announces completion of enrollment for both phase 3 #ENSURE trials in relapsing #MultipleSclerosis (#RMS) and presents additional data underlining the positive outcome of the phase 2 CALLIPER trial in progressive mulitple sclerosis (PMS) ✨ 📄 Get all the details here: bit.ly/4dOw840 #vidofludimus #IMU838 #neurology #neuroprotection #MS #PMS #MSResearch $IMUX

📢 #𝗜𝗺𝗺𝘂𝗻𝗶𝗰 𝗔𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝘀 𝗣𝗿𝗶𝗰𝗶𝗻𝗴 𝗼𝗳 𝗢𝘃𝗲𝗿𝘀𝘂𝗯𝘀𝗰𝗿𝗶𝗯𝗲𝗱 $𝟲𝟱 𝗠𝗶𝗹𝗹𝗶𝗼𝗻 𝗨𝗻𝗱𝗲𝗿𝘄𝗿𝗶𝘁𝘁𝗲𝗻 𝗣𝘂𝗯𝗹𝗶𝗰 #𝗢𝗳𝗳𝗲𝗿𝗶𝗻𝗴 💰 Today, we announced the pricing of an underwritten #PublicOffering, securing approx. $65 million in initial gross proceeds, with the potential to receive up to an aggregate of $130 million of additional gross proceeds if all tranches are exercised in full for cash. 📈 The net proceeds will support the continued advancement of our clinical development pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, as well as general corporate purposes. 🔗 Learn more here: bit.ly/3HtI2UU $IMUX #immunology #biotechnology

🚨 #𝗜𝗺𝗺𝘂𝗻𝗶𝗰 𝗔𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝘀 𝗣𝗼𝘀𝗶𝘁𝗶𝘃𝗲 𝗣𝗵𝗮𝘀𝗲 𝟮 #𝗖𝗔𝗟𝗟𝗜𝗣𝗘𝗥 𝗧𝗿𝗶𝗮𝗹 𝗥𝗲𝘀𝘂𝗹𝘁𝘀! 🚨 Key highlights: 🔹 20% reduction in relative risk of 24-week confirmed disability worsening (24wCDW) events in overall #PMS study population compared to placebo 🔹 30% reduction in relative risk of 24wCDW events compared to placebo in high unmet need population of #PPMS 🔹 Consistent reduction of disability worsening in subpopulations without inflammatory lesions at baseline 🔹 29% reduction in relative risk of 24wCDW events in patients without gadolinium-enhancing lesions at baseline compared to placebo 🔹 20% reduction in annualized rate of thalamic brain volume loss compared to placebo 🔹 Confirmed favorable safety and tolerability profile observed in previous clinical trials; no new safety signals identified 👉 Join our webcast today at 8am ET: bit.ly/4iDSTZs All details: ▶️ bit.ly/42XimHr #vidofludimus #IMU838 #MultipleSclerosis #MS #neurology $IMUX

🧠 How is #Immunic advancing potential new #MS treatment options? Our phase 3 #ENSURE trials can continue as planned, according to a recent positive interim analysis. Learn more details in @BioWorld’s latest article: ➡️ bit.ly/3NHoTid #MultipleScerlosis #PMS #RMS #Vidofludimus $IMUX #Immunic

📢$IMUX announced a 𝗽𝗼𝘀𝗶𝘁𝗶𝘃𝗲 outcome of the phase 3 #ENSURE interim analysis of #vidofludimus calcium in #RMS! An unblinded IDMC confirmed futility criteria were not met & recommended continuing the trial without changes. Learn more details here: ▶ bit.ly/4dUGzld or join #Immunic's webcast today 8am ET: ▶ bit.ly/48n36Gg #ClinicalTrials #IMU838 #MS #MultipleSclerosis #Neuroprotection #Nurr1 #DHODH

🙏 As #ECTRIMS2024 comes to a close, the $IMUX team is grateful to everyone who made it so valuable! 🤝 Thank you to all who stopped by to meet with us. Together, we are moving forward to find new treatments for progressive and relapsing #MultipleSclerosis. @ECTRIMS #MS #Immunic

@DrYukselUrun @ImmunicInc @JessyBrett @Nasdaq Thank you @DrYukselUrun

@gladdinesw @ImmunicInc @JessyBrett @Nasdaq Congratulations Werner, wish you all the success in your new role.

I am honored and excited about my new role as Chief Development Officer at @ImmunicInc. The Nasdaq tower display is a proud moment, and I am grateful for the team's support and hard work that made this possible. A big thank you to @JessyBrett and the @Nasdaq team for the gesture

🎉 Congratulations, once again, on your #promotion to Chief Development Officer, Werner! Your hard work and dedication have truly paid off. This display at the #Nasdaq tower is well-deserved. Here's to many more successes and milestones ahead! 👏 $IMUX #Immunic @NasdaqExchange

Join us in welcoming @ImmunicInc to the Closing Bell. 🛎️ $IMUX is developing a pipeline of next-generation selective oral therapies focused on offering patients with chronic inflammatory and autoimmune diseases new and clinically meaningful treatment options. #NasdaqListed

nasdaq.com/events/immunic… Immunic rings the closing bell

Thank you, @TheStevieAwards for rewarding us with 3 Gold & 1 Bronze Stevie Awards for our #MS R&D Webcast & website design. Now, we want to challenge our team even further & secure the prize for the most creative winning photo. Please like, retweet & support! #StevieWinner2023

Today, 9:30am-4:00pm CT, at @DDWMeeting, Dr. Franziska Buriánek, Senior Medical Director at $IMUX, presents an e-poster, entiteled: "First-in-Human Trial of #IMU856, an Orally Available Regulator Of Barrier Function For The Treatment Of #CeliacDisease". #DDW #DDW2023 #Immunic

‼️NEWS‼️ During @DDWMeeting, today, we present clinical and preclinical data of #IMU856, including its #ModeOfAction as a potent small molecule modulator of #SIRT6. Learn more: bit.ly/3NKa9jP #DigestiveDiseaseWeek #DDW #DDW2023 #Immunic $IMUX

▶️May 3-4: Meet $IMUX's VP, Clinical Development Operations, Werner Gladdines at the "Outsourcing in Clinical Trials (OCT) Europe". Let's learn about #FutureTrends and get the latest knowledge about disruptors in the #ClinicalTrials space. @Arena_Pharma #OCTEurope2023

Exciting times at Immunic. The clinical development operations group is further expanding its capabilities with 2 new exciting roles in the area of clinical compliance and vendor management. These roles have direct impact on the future of our three oral s…lnkd.in/ewFU48FZ

Today is #WorldIBDDay2022! $IMUX is developing a potential therapy to alleviate the suffering of people with #UlcerativeColitis. #VidofludimusCalcium is in a phase 2 clinical trial in moderate-to-severe #UC, for which top-line data is expected in June. #IBDhasNoAge #GameOverIBD

$IMUX to participate in upcoming conferences: bit.ly/36HDHvk @BRileyFinancial Neuro & Ophthalmology Conference (Apr 27-28); @ArenaIntOCT Outsourcing in Clinical Trials Europe (May 4-5); @BioCentury #BioEquity Europe (May 16-18; 23-24); @DDWMeeting #DDW2022 (May 21-24)